Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). | Available online http content 1 2 2 R45 Research Protein C a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa activated Andrew F Shorr1 David R Nelson2 Duncan LA Wyncoll3 Konrad Reinhart4 Frank Brunkhorst4 George Matthew Vail2 and Jonathan Janes2 Department of Medicine Section of Pulmonary and Critical Care Medicine Washington Hospital Center Irving Street Washington District of Columbia 20010 USA 2Lilly Research Laboratories Eli Lilly and Company 520 S. Meridian Indianapolis Indiana 46285 USA department of Critical Care Guy s and St Thomas NHS Foundation Trust Lambeth Palace Road London SE1 7EH UK department of Anesthesiology and Intensive Care Friedrich Schiller University Erlanger Allee Jena 07740 Germany Corresponding author Andrew F Shorr afshorr@ Received 19 Nov 2007 Revisions requested 9 Jan 2008 Revisions received 13 Feb 2008 Published 4 Apr 2008 Critical Care 2008 12 R45 doi cc6854 This article is online at http content 12 2 R45 2008 Shorr et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Drotrecogin alfa activated DrotAA treatment a 96-hour infusion reduces 28-day mortality in severe sepsis to approximately 25 . The question remains whether a longer infusion or higher dose could increase rate of survival. The goal of this study was to identify a dependable sensitive measure with which to monitor disease progression and response in patients during DrotAA treatment. Methods Data on severe sepsis patients included in PROWESS placebo-controlled double-blind randomized study of 850 DrotAA and 840 placebo individuals and ENHANCE single-arm open-label study of 2 375 DrotAA patients .
